Experimental and Clinical Investigation of the Implant Surface Roughness Reduction Effect on Early-stage Fibrosis

Inclusion Criteria: * Age \> 18 years * Female sex * High risk family history for mammary and/or ovarian cancer * Planned prophylactic mastectomy with simultaneous breast reconstruction * Signed informed consent form Exclusion Criteria: * Confirmed sever Coagulation disorder, representing a potential contraindication for the elective surgery * Confirmed Rheumatic disease accompanied by obligatory intake of immunomodulating therapeutic agents * Confirmed severe renal functional disorder: Renal insufficiency status IV or V * Active hematological or oncological disease * HIV-Infection * Hepatitis-Infection * Pregnancy or breast feeding * Intake of anti-inflammatory drugs * Carrier of silicone implants (e.g. gastric banding, mammary implants) * Subject is currently participating or intends to participate in another clinical trial that may interfere with the protocol of this study * Patients who have implanted devices that could be affected by a magnetic field (e.g., pacemakers, drug infusion devices, artificial sensing devices) \* patients with removable devices such as removable diabetes pumps, sensors and transmitter might still part take, * Patients with alteration in hematologic and serum protein reference values post-chemotherapy. * When there is a residual malignancy in the intended expansion site. * Existing tissue at the intended expansion site is not adequate according to the surgeon's criteria, because of previous radiation therapy, ulcerations, vascular compromise, …